Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

CompletedOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

July 15, 2017

Primary Completion Date

September 15, 2017

Study Completion Date

September 15, 2017

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15/20 mg

Trial Locations (1)

US database, New York